Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Intervention...
NRX Pharmaceuticals, Inc. (NRXP)
Company Research
Source: Yahoo! Finance
AI-powered "Depression Thermometer" across its interventional psychiatry clinic network. Emobot's platform passively monitors depression, bipolar disorder and anxiety disorders via smartphone — replacing burdensome questionnaires with background analysis of facial expressions, vocal tones, and actigraphy. The partnership targets the critical "blind spot" in TRD care: ~50% of patients relapse within 6–12 months, often undetected between clinic visits. Clinical validation across three prospective studies shows strong concordance with MADRS (r=0.89) and PHQ-9 (r=0.83), providing an objective, real-time biomarker stream for clinicians. The integration is expected to double patient success rates by enabling timely "recapture" interventions — such as maintenance ketamine or TMS sessions — the moment early relapse signals are detected. Patients gain real-time mood, and activity insights through the Emobot app, with automatic notifications and in-app appointment scheduling if relaps
Show less
Read more
Impact Snapshot
Event Time:
NRXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRXP alerts
High impacting NRX Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
NRXP
News
- NRx Pharmaceuticals (NRXP) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $34.00 price target on the stock.MarketBeat
- NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality [Yahoo! Finance]Yahoo! Finance
- NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and SuicidalityGlobeNewswire
- NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder ApplicationsGlobeNewswire
- NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial OfficerGlobeNewswire
NRXP
Earnings
- 11/14/25 - Miss
NRXP
Sec Filings
- 3/24/26 - Form 8-K
- 3/23/26 - Form 10-K
- 2/24/26 - Form DEFA14A
- NRXP's page on the SEC website